66 related articles for article (PubMed ID: 3713925)
1. Cancer chemotherapy induces a transient increase of serum-iron level.
Follézou JY; Bizon M
Neoplasma; 1986; 33(2):225-31. PubMed ID: 3713925
[TBL] [Abstract][Full Text] [Related]
2. [Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron due to hemolysis after chemotherapy including 5-FU].
Hosokawa Y; Motoori S; Miyazawa T; Iwamoto N; Kase Y; Kitagawa N; Saisho H; Furuse J; Itabashi M
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1805-8. PubMed ID: 20841952
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of swainsonine in patients with advanced malignancies.
Goss PE; Baptiste J; Fernandes B; Baker M; Dennis JW
Cancer Res; 1994 Mar; 54(6):1450-7. PubMed ID: 8137247
[TBL] [Abstract][Full Text] [Related]
5. Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patients.
Lissoni P; Cazzaniga M; Ardizzoia A; Rossini F; Fiorelli G; Tancini G; Pittalis S; Barni S
J Biol Regul Homeost Agents; 1993; 7(1):31-3. PubMed ID: 8346713
[TBL] [Abstract][Full Text] [Related]
6. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
8. Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy.
Lalle M; Pistillucci G; Antimi M; D'Aprile M
J Exp Clin Cancer Res; 2005 Jun; 24(2):197-201. PubMed ID: 16110751
[TBL] [Abstract][Full Text] [Related]
9. The status of serum iron and transferrin saturation in acute non-hepatotrophic viral infections.
Brill S; Weinberg M; Graff E; Moshkowitz M; Oren R
J Med; 2000; 31(5-6):271-7. PubMed ID: 11508320
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
[TBL] [Abstract][Full Text] [Related]
12. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
González-Barón M; Ordóñez A; Franquesa R; Constenla M; Montalar J; Gili F; Camps C; Sancho JF; Pérez-Cachot P
Cancer; 2002 Dec; 95(11):2408-13. PubMed ID: 12436449
[TBL] [Abstract][Full Text] [Related]
13. Effect of repeated apotransferrin administrations on serum iron parameters in patients undergoing myeloablative conditioning and allogeneic stem cell transplantation.
Parkkinen J; Sahlstedt L; von Bonsdorff L; Salo H; Ebeling F; Ruutu T
Br J Haematol; 2006 Oct; 135(2):228-34. PubMed ID: 16925790
[TBL] [Abstract][Full Text] [Related]
14. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
15. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B.
Bayraktar Y; Saglam F; Temizer A; Uzunalimodlu B; van Thiel DH
Hepatogastroenterology; 1998; 45(24):2322-7. PubMed ID: 9951916
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of iron, nutritional status indexes and acute phase protein in acute coronary syndromes.
Mattioli AV; Bonetti L; Zennaro M; Ripa S; Mattioli G
Ital Heart J; 2002 Mar; 3(3):194-8. PubMed ID: 11974664
[TBL] [Abstract][Full Text] [Related]
17. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
18. Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin.
Cerruti A; Castello G; Balleari E; Bogliolo G; Lerza R; Pannacciulli I
Exp Hematol; 1994 Dec; 22(13):1261-3. PubMed ID: 7957712
[TBL] [Abstract][Full Text] [Related]
19. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
20. Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer.
Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
Oncol Rep; 2005 Aug; 14(2):433-9. PubMed ID: 16012727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
